PD 102807Selective M4 antagonist CAS# 23062-91-1 |
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- Nu 6027
Catalog No.:BCC1154
CAS No.:220036-08-8
- R547
Catalog No.:BCC3927
CAS No.:741713-40-6
- Palbociclib (PD0332991) Isethionate
Catalog No.:BCC3698
CAS No.:827022-33-3
- AT7519
Catalog No.:BCC2541
CAS No.:844442-38-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 23062-91-1 | SDF | Download SDF |
| PubChem ID | 4995951 | Appearance | Powder |
| Formula | C23H24N2O4 | M.Wt | 392.45 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| SMILES | CCOC(=O)C1=C(NC2=C1C3=C(C=C2)OC4C5=C(CCN4C3)C=C(C=C5)OC)C | ||
| Standard InChIKey | VDDUJINYXKGZLV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H24N2O4/c1-4-28-23(26)20-13(2)24-18-7-8-19-17(21(18)20)12-25-10-9-14-11-15(27-3)5-6-16(14)22(25)29-19/h5-8,11,22,24H,4,9-10,12H2,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective M4 muscarinic receptor antagonist. IC50 values are 91, 6559, 3441, 950 and 7412 nM for human M4, M1, M2, M3, and M5 receptors respectively. |
PD 102807 Dilution Calculator
PD 102807 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5481 mL | 12.7405 mL | 25.481 mL | 50.9619 mL | 63.7024 mL |
| 5 mM | 0.5096 mL | 2.5481 mL | 5.0962 mL | 10.1924 mL | 12.7405 mL |
| 10 mM | 0.2548 mL | 1.274 mL | 2.5481 mL | 5.0962 mL | 6.3702 mL |
| 50 mM | 0.051 mL | 0.2548 mL | 0.5096 mL | 1.0192 mL | 1.274 mL |
| 100 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.5096 mL | 0.637 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Eurycomalactone
Catalog No.:BCN3108
CAS No.:23062-24-0
- Varenicline Hydrochloride
Catalog No.:BCC4156
CAS No.:230615-23-3
- Sinensetin
Catalog No.:BCN6356
CAS No.:2306-27-6
- (-)-Sophoranone
Catalog No.:BCN7162
CAS No.:23057-55-8
- L-AP4
Catalog No.:BCC6550
CAS No.:23052-81-5
- Dihydroconiferyl alcohol
Catalog No.:BCN7047
CAS No.:2305-13-7
- Lofepramine
Catalog No.:BCC7402
CAS No.:23047-25-8
- Ajugasterone C
Catalog No.:BCN2757
CAS No.:23044-80-6
- Z-Arg(NO2)-OH
Catalog No.:BCC3063
CAS No.:2304-98-5
- Z-Asn-OH
Catalog No.:BCC2794
CAS No.:2304-96-3
- Z-β-Ala-OH
Catalog No.:BCC3058
CAS No.:2304-94-1
- Terbutaline Sulfate
Catalog No.:BCC4320
CAS No.:23031-32-5
- 4-Amino-N-methylphthalimide
Catalog No.:BCC8686
CAS No.:2307-00-8
- Xylazine HCl
Catalog No.:BCC4341
CAS No.:23076-35-9
- Sitosteryl palmitate
Catalog No.:BCN5078
CAS No.:2308-85-2
- 2-amino-3-(3-bromo-5-chloro-4-hydroxyphenyl)propanoic acid
Catalog No.:BCN8284
CAS No.:
- Corilagin
Catalog No.:BCN2322
CAS No.:23094-69-1
- Chebulagic acid
Catalog No.:BCN3262
CAS No.:23094-71-5
- Neuropeptide SF (mouse, rat)
Catalog No.:BCC6054
CAS No.:230960-31-3
- UK 356618
Catalog No.:BCC2378
CAS No.:230961-08-7
- UK 370106
Catalog No.:BCC2379
CAS No.:230961-21-4
- Fumagillin
Catalog No.:BCC2347
CAS No.:23110-15-8
- Methylxanthoxylin
Catalog No.:BCC8212
CAS No.:23121-32-6
- Lapatinib
Catalog No.:BCC3633
CAS No.:231277-92-2
PD 102807, a novel muscarinic M4 receptor antagonist, discriminates between striatal and cortical muscarinic receptors coupled to cyclic AMP.[Pubmed:10576595]
Life Sci. 1999;65(21):2233-40.
In membranes of Chinese hamster ovary cells expressing the cloned human M1-M4 muscarinic receptor subtypes, PD 102807, a novel M4 selective antagonist, was found to counteract the M4 receptor-induced stimulation of [35S]-GTPgammaS binding to membrane G proteins with a pK(B) of 7.40, a value which was 63-, 33- and 10-fold higher than those displayed at M1 (pK(B) = 5.60), M2 (pK(B) = 5.88) and M3 (pK(B) = 6.39) receptor subtypes, respectively. In rat striatal membranes, PD 102807 antagonized the muscarinic inhibition of dopamine (DA) D1 receptor-stimulated adenylyl cyclase with a pK(B) value of 7.36. In contrast, in membranes of rat frontal cortex, PD 102807 displayed lower potencies in antagonizing either the muscarinic facilitation of corticotropin releasing hormone (CRH)-stimulated adenylyl cyclase (pK(B) = 5.79) or inhibition of Ca2+/calmodulin (Ca2+/CaM)-stimulated enzyme activity (pK(B) = 5.95). In each response investigated, PD 102807 interacted with muscarinic receptors in a manner typical of a simple competitive antagonist. These data provide additional evidence that PD 102807 is a M4-receptor preferring antagonist and that this compound can discriminate the striatal muscarinic receptors inhibiting DA D1 receptor activity from the cortical receptors mediating the potentiation of CRH receptor signalling and the inhibition of Ca2+/CaM-stimulated adenylyl cyclase activity.
Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors.[Pubmed:12086495]
J Med Chem. 2002 Jul 4;45(14):3094-102.
Previously, we reported on PD 102807 (41) as being the most selective synthetic M(4) muscarinic antagonist identified to date. Synthesized analogues of 41 showed no improvement in affinity and selectivity at that time. However, several newly synthesized compounds exhibit a 7-fold higher affinity at M(4) receptors and demonstrate a selectivity of at least 100-fold over all other muscarinic receptor subtypes. For example, compound 28 showed an affinity of pK(i) = 9.00 at M(4) receptors and a selectivity of M(1)/M(4) = 13 183-fold, M(2)/M(4) = 339-fold, M(3)/M(4) = 151-fold, and M(5)/M(4) = 11 220-fold. This high selectivity along with high affinity has not been reported for any synthetic muscarinic antagonist, nor for natural occurring M(4) antagonists such as the M(4) selective Eastern Green Mamba venom MT3 (M(4) pK(b) = 8.7, M(1)/M(4) = 40-fold, M(2)/M(4) > or = 500-fold, M(3)/M(4) > or = 500-fold, and M(5)/M(4) > or = 500-fold). Derivative 24, a compound with a high selectivity pattern as well, has been tested for in vivo efficacy. It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1017, an M(1)/M(4) selective muscarinic agonist, in the mesolimbic region and striatum, which suggests that 24 is capable of crossing the blood-brain barrier and confirms the pharmacokinetic data obtained on this compound. This is evidence that suggests that agonist-induced increase in catecholamine synthesis observed in these regions is mediated by M(4) receptors.
A novel muscarinic M(4) receptor antagonist provides further evidence of an autoreceptor role for the muscarinic M(2) receptor sub-type.[Pubmed:10556681]
Eur J Pharmacol. 1999 Oct 21;383(1):53-6.
Muscarinic M(2) (AF-DX 384, BIBN-161) and M(4) (PD102807) receptor antagonists were used to investigate the respective roles of these two receptor sub-types in the regulation of acetylcholine release in the rat hippocampus. In vivo dialysis studies revealed that only the muscarinic M(2) receptor antagonists significantly and concentration-dependently facilitate acetylcholine release. The newly developed muscarinic M(4) receptor antagonist was unable to regulate acetylcholine release except at the highest concentration tested. It would thus appear that the muscarinic receptor acting as negative autoreceptor in the rat hippocampus is of the muscarinic M(2) sub-type, the role of the muscarinic M(4) receptor being minimal in this regard.
Identification and characterization of m4 selective muscarinic antagonists.[Pubmed:9873472]
Bioorg Med Chem Lett. 1998 Aug 4;8(15):1991-6.
Our interest in the area of m4 muscarinic antagonists had led us to study a series of benzoxazine isoquinolines. One of the most potent and selective compounds of this series is example 1 with an IC50 value of 90.7 nM at m4 receptors, and 72-fold (m1), 38-fold (m2), 10-fold (m3), and 82-fold (m5) more selective compared to the other receptors. The synthesis and receptor binding affinity of analogs of 1 are reported.
